- Copyright - Il Pensiero Scientifico Editore downloaded by IP 18.97.9.174 Fri, 06 Nov 2026, 23:25:52

Prescrire INTERNATIONAL

A critical eye on new drugs authorised in Europe

n° 284 SEPTEMBER 2026

Editorial

Victims of drug-induced harms: the need for recognition

Marketing Authorisations

Zuranolone (Zurzuvae°) in postpartum depression

Omaveloxolone (Skyclarys°) in Friedreich's ataxia

Pegylated liposomal irinotecan (Onivyde Pegylated Liposomal°) in first-line treatment of metastatic pancreatic cancer

Mirvetuximab soravtansine (Elahere°) in certain ovarian cancers

Apixaban (Eliquis°) in venous thromboembolism in children and adolescents

Talazoparib (Talzenna°) + enzalutamide in metastatic prostate cancer resistant to androgen deprivation therapy

Ipilimumab (Yervoy°) + nivolumab (Opdivo°) as first-line treatment in certain rare types of colorectal cancer

Adverse Effects

In-utero exposure to PD-1 and PD-L1 inhibitors: autoimmune disorders?

In-utero exposure to paracetamol and neuropsychological development (continued)

Editors' opinion. State-approved disinformation depriving patients of potential benefit

In-utero exposure to caftors: no significant safety signals in the short term

Common stem: -cept

Outlook

Compensation for victims of drug-induced harms: new European directive is welcome, but unlikely to have a major impact

Mental health policy: the neurobiology offensive

https://english.prescrire.org/en/Summary.aspx

September 26 – Vol 64 – 9

- **Editorial**
  Can we do more to address long-term harms of medicine use? Learning from the DES (diethylstilboestrol) disaster *(3 September, 2026)*
  Barbara Mintzes, Carol Devine
  FREE

- **Commentary**
  Precision medicine arrives in COPD
  (3 September, 2026)
  Gordon Mallarkey

- **Reviews**
  Pharmacological treatment of polyendocrine metabolic ovarian syndrome in adults
  (1 July, 2026)
  Lucy Prentice, Kate Rassie

  Update on spasticity: part 1 – background and diagnosis *(11 May, 2026)*
  Ikechukwu Chukwuocha, Krishnan Padmakumari Sivaraman Nair

- **DTB select**
  Study confirms benefits of continuous glucose monitoring in type 2 diabetes *(15 June, 2026)*

https://dtb.bmj.com/content/64/9?current-issue=y